With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Life quality after childhood cancer is quantifiable thanks to outcome indicators.

2.

"We Caught It Early": Advantage or Disadvantage?

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

A protein with new anticancer activity has been identified

5.

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot